Difference between revisions of "Libre Pathology talk:Study Group"

Jump to navigation Jump to search
no edit summary
Line 51: Line 51:


These are some questions I came up with that are plausible to me... let me know if they are out to lunch.  
These are some questions I came up with that are plausible to me... let me know if they are out to lunch.  
==Molecular Pathology Rotation Notes==


===UNIT 1===
===UNIT 1===
{{hidden|List three differences between DNA and RNA.|[[DNA (double stranded, thymine, deoxyribose, more stable; RNA single stranded, ribose, uracil]]}}
{{hidden|List three differences between DNA and RNA.|[[DNA (double stranded, thymine, deoxyribose, more stable; RNA single stranded, ribose, uracil]]}}


Line 68: Line 71:


{{hidden|What is the difference between a missense and a non-sense mutation?|<center>[[Missense the new base pair does not change the amino acid found in the protein at that location, non-sense changes the amino acid in the protein at that location]]</center>}}
{{hidden|What is the difference between a missense and a non-sense mutation?|<center>[[Missense the new base pair does not change the amino acid found in the protein at that location, non-sense changes the amino acid in the protein at that location]]</center>}}
{{hidden|Define a frameshift mutation. |<center>[[deletion of a non-multiple of 3 which causes all further trinucleotide combinations to no longer code for the correct amino acid, often results in a premature stop codon]]</center>}}
{{hidden|Define a frameshift mutation. |<center>[[deletion of a non-multiple of 3 which causes all further trinucleotide combinations to no longer code for the correct amino acid, often results in a premature stop codon]]</center>}}
{{hidden|Why are inversion mutations difficult to detect?|<center>[[When the are smal, e.g. only a few base pairs]]</center>}}
{{hidden|Why are inversion mutations difficult to detect?|<center>[[When the are smal, e.g. only a few base pairs]]</center>}}
{{hidden|Describe the potential sequelae of a translocation mutation. |<center>[[when a segment on one chromosome is transferred to another, make a gene non-functional or can result in a fusion gene]]</center>}}
{{hidden|Describe the potential sequelae of a translocation mutation. |<center>[[when a segment on one chromosome is transferred to another, make a gene non-functional or can result in a fusion gene]]</center>}}


===UNIT 2===
===UNIT 2===
{{hidden|Translate the following: c.1524_1527delCGTA.|<center>[[a small deletion  of CGTA between the 1524 and 1527 base pairs]]</center>}}
{{hidden|Translate the following: c.1524_1527delCGTA.|<center>[[a small deletion  of CGTA between the 1524 and 1527 base pairs]]</center>}}
{{hidden|List 5 features of SNPs.|<center>[[most common DNA sequence variation in humans, must occur in >=1% of a particular population, frequency of SNPs varies by groups, but responsible for >90% of human genetic variation, an can be found in any region of genome]]</center>}}
 
{{hidden|Define a regulatory SNP and a synonymous SNP?|<center>[[Regulatory SNP: occur in non-coding regions e.g. promoters where they affect mRNA expression and stability, as occur in the splice site where can result in abnormal protein production]]</center>}}
{{hidden|List 5 features of SNPs.|[[Most common DNA sequence variation in humans, must occur in >=1% of a particular population, frequency of SNPs varies by groups, but responsible for >90% of human genetic variation, an can be found in any region of genome]]}}
 
{{hidden|Define a regulatory SNP versus a synonymous SNP?|[[Regulatory SNP: occur in non-coding regions e.g. promoters where they affect mRNA expression and stability, as occur in the splice site where can result in abnormal protein production]]}}
 
{{hidden|What is the difference between a microstalellite and a minisattelite?|<center>[[Microsatellite = stretches of DNA with sequences of 2-4 base pairs repeated a few dozen times (STRP), minisatellite = variable number of tandem repeats 10-100bp in lenght]]</center>}}
{{hidden|What is the difference between a microstalellite and a minisattelite?|<center>[[Microsatellite = stretches of DNA with sequences of 2-4 base pairs repeated a few dozen times (STRP), minisatellite = variable number of tandem repeats 10-100bp in lenght]]</center>}}
{{hidden|Describe Hardy-Weinberg Equilibrium?|<center>[[Mathematical probability function to describe allelic and genotype frequency in a random mating scenario]]</center>}}
{{hidden|Describe Hardy-Weinberg Equilibrium?|<center>[[Mathematical probability function to describe allelic and genotype frequency in a random mating scenario]]</center>}}
{{hidden|What factors can disrupt the H-W equilibrium?|<center>[[non random mating, migration, genetic drift, founder effects, mutation, natural selection]]</center>}}
{{hidden|What factors can disrupt the H-W equilibrium?|<center>[[non random mating, migration, genetic drift, founder effects, mutation, natural selection]]</center>}}
{{hidden|What is linkage disequilibrium?|<center>[[The closer two genes are together on the chromosome the more likely they are to be found toghether in a population, during meiosis some exchange of material happens between the two chromosomes]]</center>}}
{{hidden|What is linkage disequilibrium?|<center>[[The closer two genes are together on the chromosome the more likely they are to be found toghether in a population, during meiosis some exchange of material happens between the two chromosomes]]</center>}}


===UNIT 3===
===UNIT 3===
{{hidden|What are the three major steps of PCR?|<center>[[denaturing, primer annealing, strand extending]]</center>}}
{{hidden|What are the three major steps of PCR?|<center>[[denaturing, primer annealing, strand extending]]</center>}}
{{hidden|What is the hallmark of PCR?|<center>[[The cycling at different temperatures, in the presence of key reaction components to traget and exponentially amplify a specific DNA target sequence]]</center>}}
{{hidden|What is the hallmark of PCR?|<center>[[The cycling at different temperatures, in the presence of key reaction components to traget and exponentially amplify a specific DNA target sequence]]</center>}}
{{hidden|What factors affect the method of genotyping chosen?|<center>[[throughput, type of variants that can be genotyped, equipment and costs, TAT, technical expertise, and multiplex ability]]</center>}}
{{hidden|What factors affect the method of genotyping chosen?|<center>[[throughput, type of variants that can be genotyped, equipment and costs, TAT, technical expertise, and multiplex ability]]</center>}}
{{hidden|Define sensitivity, specificity, positive predictive value and negative predictive value. |<center>[[Sensitivity = probability of a positive test in a disease, specificity = probability of a negative dest in a non-diseased patient ]]</center>}}
{{hidden|Define sensitivity, specificity, positive predictive value and negative predictive value. |<center>[[Sensitivity = probability of a positive test in a disease, specificity = probability of a negative dest in a non-diseased patient ]]</center>}}
{{hidden|Define reproducibility and accuracy of an analytical test. |<center>[[Reproducability = probability of the test repeatedly producing the same reults in the same person, Accuracy = the degree to which the observed genotype matches the true genotype]]</center>}}
 
{{hidden|Define reproduciblity and accuracy of an analytical test. |<center>[[Reproducability = probability of the test repeatedly producing the same reults in the same person, Accuracy = the degree to which the observed genotype matches the true genotype]]</center>}}
 
{{hidden|Describe briefly Sanger sequencing.|<center>[[DIdeoxynucleotides are used in a mix with deoxynucleotides, the Di*** terminate the chain, and so you get all possible lengths of chains so then you put them all in order and you can read (based on weight) which one is at each position]]</center>}}
{{hidden|Describe briefly Sanger sequencing.|<center>[[DIdeoxynucleotides are used in a mix with deoxynucleotides, the Di*** terminate the chain, and so you get all possible lengths of chains so then you put them all in order and you can read (based on weight) which one is at each position]]</center>}}
{{hidden|Describe briefly how Taqman automated genotyping is used for allele detection. |<center>[[Microsatellite instability]]</center>}}
{{hidden|Describe briefly how Taqman automated genotyping is used for allele detection. |<center>[[Microsatellite instability]]</center>}}
{{hidden|How are DNA microarrays used to identify drug disposition or responses?|<center>[[Microsatellite instability]]</center>}}
{{hidden|How are DNA microarrays used to identify drug disposition or responses?|<center>[[Microsatellite instability]]</center>}}


===UNIT 4===
===UNIT 4===
{{hidden|Describe the procedure for submitting FFPE slides for KRAS for colorectal cancer.|<center>[[Microsatellite instability]]</center>}}
{{hidden|Describe the procedure for submitting FFPE slides for KRAS for colorectal cancer.|<center>[[Microsatellite instability]]</center>}}
{{hidden|Compare and contrast uniplex versus multiplex genotyping. |<center>[[Microsatellite instability]]</center>}}
{{hidden|Compare and contrast uniplex versus multiplex genotyping. |<center>[[Microsatellite instability]]</center>}}
{{hidden|Compare and contrast conventional vs massively parallel sequencing. |<center>[[Microsatellite instability]]</center>}}
{{hidden|Compare and contrast conventional vs massively parallel sequencing. |<center>[[Microsatellite instability]]</center>}}
{{hidden|What is multiplex ligation-dependent ligation (MLPA)?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is multiplex ligation-dependent ligation (MLPA)?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is fragment analysis?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is fragment analysis?|<center>[[Microsatellite instability]]</center>}}
{{hidden|Compare and contrast RT-PCR vs qRTPCR.|<center>[[Microsatellite instability]]</center>}}
{{hidden|Compare and contrast RT-PCR vs qRTPCR.|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is MSI?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is MSI?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is methylation analysis?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is methylation analysis?|<center>[[Microsatellite instability]]</center>}}


===UNIT 5===
===UNIT 5===
{{hidden|What are the four test features required to be documented by the CLIA?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What are the four test features required to be documented by the CLIA?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What are "in vitro diagnostics" vs "laboratory developed tests"?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What are "in vitro diagnostics" vs "laboratory developed tests"?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What does validation mean? |<center>[[Microsatellite instability]]</center>}}
{{hidden|What does validation mean? |<center>[[Microsatellite instability]]</center>}}
{{hidden|What are the four performance characteristics that need to be verified for FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What are the four performance characteristics that need to be verified for FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What are the six performance characteristics that need to be verified for FDA cleared LDTs or modified FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What are the six performance characteristics that need to be verified for FDA cleared LDTs or modified FDA cleared/approved tests?|<center>[[Microsatellite instability]]</center>}}


===UNIT 6===
===UNIT 6===
{{hidden|List the components of a molecular pathology report.|<center>[[Microsatellite instability]]</center>}}
{{hidden|List the components of a molecular pathology report.|<center>[[Microsatellite instability]]</center>}}
{{hidden|Define analytical sensitivity and clinical sensitivity. |<center>[[Microsatellite instability]]</center>}}
{{hidden|Define analytical sensitivity and clinical sensitivity. |<center>[[Microsatellite instability]]</center>}}
{{hidden|What should be said in a report of a molecular test on a patient for residual disease if no previous positive assay was confirmed?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What should be said in a report of a molecular test on a patient for residual disease if no previous positive assay was confirmed?|<center>[[Microsatellite instability]]</center>}}
{{hidden|Define ammended report versus addendum report.|<center>[[Microsatellite instability]]</center>}}
{{hidden|Define ammended report versus addendum report.|<center>[[Microsatellite instability]]</center>}}
{{hidden|Whose responsibility is it to sythesize the test results with other clinico-pathological information?|<center>[[Microsatellite instability]]</center>}}
{{hidden|Whose responsibility is it to sythesize the test results with other clinico-pathological information?|<center>[[Microsatellite instability]]</center>}}
{{hidden|How long are cytogenetic reports required to be kept by CAP?|<center>[[Microsatellite instability]]</center>}}
{{hidden|How long are cytogenetic reports required to be kept by CAP?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is the recommended process to use test results if an assay is not yet validated for clinical use?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What is the recommended process to use test results if an assay is not yet validated for clinical use?|<center>[[Microsatellite instability]]</center>}}
{{hidden|Give three examples of "grey areas" which warrant discretion of professionals involved to use a non-validated test?|<center>[[Microsatellite instability]]</center>}}
{{hidden|Give three examples of "grey areas" which warrant discretion of professionals involved to use a non-validated test?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What reference standard is available for gene nomenclature?|<center>[[Microsatellite instability]]</center>}}
{{hidden|What reference standard is available for gene nomenclature?|<center>[[Microsatellite instability]]</center>}}
{{hidden|Create a table of the most common gene rearrangements associated with heme and soft tissue diseases. |<center>[[Microsatellite instability]]</center>}}
{{hidden|Create a table of the most common gene rearrangements associated with heme and soft tissue diseases. |<center>[[Microsatellite instability]]</center>}}
{{hidden|What is a "DNA fingerprint" and what can it be used for?|<center>[[A method that examines multiple areas of short tandem repeats to identify paternity, mosaicism, chimerism, and identity in forensics cases]]</center>}}


{{hidden|What is a "DNA fingerprint" and what can it be used for?|<center>[[A method that examines multiple areas of short tandem repeats to identify paternity, mosaicism, chimerism, and identity in forensics cases]]
</center>}}


===Robbins and Cotran Chapter 5 9th Edition===
 
==Robbins and Cotran Chapter 5 9th Edition:==


{{hidden|MC cause of spontaneous abortion is ?|<center>[[ A demonstrable chromosomal abnormality.]]</center>}}
{{hidden|MC cause of spontaneous abortion is ?|<center>[[ A demonstrable chromosomal abnormality.]]</center>}}
Line 143: Line 184:
iv. Those influenced by gonadal mosaicism]]</center>}}
iv. Those influenced by gonadal mosaicism]]</center>}}


{{hidden|List and describe the possible outcomes of a point mutation in a coding region?|<center>[[a. Missense mutation – pt mutation changes amino acid code, conservative when the amino acid is preserved, non conservative when replaced with another amino acid
{{hidden|List and describe the possible outcomes of a point mutation in a coding region?|[[a. Missense mutation – pt mutation changes amino acid code, conservative when the amino acid is preserved, non conservative when replaced with another amino acid, b. Nonsense mutation – makes a stop codon ]]</center>}}
b. Nonsense mutation – makes a stop codon ]]</center>}}


{{hidden|List and describe the possible outcomes of point mutation or deletion in a non-coding region.|<center>[[a. Promoters/enhancers – interfere with binding of transcription factors, marker reduction or total lack of transcription, b. Introns – defective splicing > failure to make mature RNA > no translation]]</center>}}
{{hidden|List and describe the possible outcomes of point mutation or deletion in a non-coding region.|<center>[[a. Promoters/enhancers – interfere with binding of transcription factors, marker reduction or total lack of transcription, b. Introns – defective splicing > failure to make mature RNA > no translation]]</center>}}
{{hidden|List and describe the possible outcomes of deletions and insertions.|<center>[[a. Small coding: not multiple of three = frameshift, if multiple of 3 than add or del amino acids accordingly, often premature stop codon
i. Tay Sachs disease: 4 base pair insertion in Hexosaminidase A gene
{{hidden|List and describe the possible outcomes of trinucleotide repeat mutations.
a. Usually G&C, dynamic and increase during gametogenesis, “RNA stutters”
b. Fragile X – CGG 250-4000, Huntinton’s Disease * See Neuropath Notes]]</center>}}


{{hidden|List and describe the possible outcomes of deletions and insertions.|<center>[[a.Small coding: not multiple of three = frameshift, if multiple of 3 than add or del amino acids accordingly, often premature stop codon
{{hidden|List and describe three examples of inheritance of single gene mutations
i. Tay Sachs disease: 4 base pair insertion in Hexosaminidase A gene ]]}}
a. AD – manifested in the heterologous state, one parent of index case is usually affected, males and females affected and both can transmit condition
 
i. De novo cases may not have affected parent
{{hidden|List and describe the possible outcomes of trinucleotide repeat mutations.|[[a. Usually G&C, dynamic and increase during gametogenesis, “RNA stutters”,b. Fragile X – CGG 250-4000, Huntinton’s Disease ]]}}
ii. Penetrance = fraction of people with gene who have the trait
 
iii. Variable expressivity = those with mutant gene have variety of phenotypes
{{hidden|List and describe three examples of inheritance of single gene mutations|[[a. AD – manifested in the heterologous state, one parent of index case is usually affected, males and females affected and both can transmit conditioni. De novo cases may not have affected parentii. Penetrance = fraction of people with gene who have the traitiii. Variable expressivity = those with mutant gene have variety of phenotypesiv. Often age of onset is delayed so can reproduce before die from diseasev. Biochem mechanisms1. Reduced production of a protein or dysfunctional/inactive protein2. Involved in regulation of complex metabolic pathyway subject to feedback inhibition3. Key structural proteins (collagen and cytoskeleton of RBC)a. May be a dominant negative , e.g. osteogenesis imperfecta4. Gain of function are rare, 2 formsa. Increased in proteins normal function (excess enzyme activity)b. Huntinton’s diseas (abn protein accumulates, toxic to neurons)b. ARi. Largest category – both alleles at a locus are mutated1. Expression is uniform, complete penetrance common, early onset, unaffected carrier family members, mostly enzymesc. X Linkedi. All sex linked, and almost all are recessive , if Y Chromosome affected usually infertile males > no progenyii. Male expression b/c hemizygous, daughter carriers with variable phenotype because of lionization of 2nd X e.g G6DPiii. Dominant . vitamin D resistant rickets]]</center>}}
iv. Often age of onset is delayed so can reproduce before die from disease
 
v. Biochem mechanisms
1. Reduced production of a protein or dysfunctional/inactive protein
2. Involved in regulation of complex metabolic pathyway subject to feedback inhibition
3. Key structural proteins (collagen and cytoskeleton of RBC)
a. May be a dominant negative , e.g. osteogenesis imperfecta
4. Gain of function are rare, 2 forms
a. Increased in proteins normal function (excess enzyme activity)
b. Huntinton’s diseas (abn protein accumulates, toxic to neurons)
b. AR
i. Largest category – both alleles at a locus are mutated
1. Expression is uniform, complete penetrance common, early onset, unaffected carrier family members, mostly enzymes
c. X Linked
i. All sex linked, and almost all are recessive , if Y Chromosome affected usually infertile males > no progeny
ii. Male expression b/c hemizygous, daughter carriers with variable phenotype because of lionization of 2nd X e.g G6DP
iii. Dominant . vitamin D resistant rickets]]</center>}}
Stopped at P142
Stopped at P142


Molecular Genetic Diagnosis
=== Molecular Genetic Diagnosis===
1. List three basic molecular diagnostic techniques
{{hidden|List three basic molecular diagnostic techniques|[[a. Karyotyping, b. Southern blot, c. Sanger DNA sequencing, d. Polymerase chain reaction]]}}
a. Karyotyping
 
b. Southern blot
 
c. Sanger DNA sequencing
===CAP Molecular Diagnosis of Lung Cancer===
d. Polymerase chain reaction
 
2. Constitutional vs somatic mutations.
{{hidden|List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration|[[1. 100% of CML: BRR-ABL > Imatinib, 2. 20% of Lung Adenocarcinoma: EGFR > Erlotinib/Gefitinib, 3. 25% Infiltrative ductal carcinoma of breast HER2>Trastuzumab, 4. 50% of Melanoma, BRAF v600E > PLX4032, 5. 4% of Lung Adenocarcinoma: ALK > Crizotinib]]}}
 
{{hidden|List and describe 5 areas of Genetic characaterization of tumours for personalized medicine|[[DNA mutations, DNA chromosomal alterations, mRNA and MiRNA profiling, Proteomics, DNA epigenetics]]}}
 
{{hidden|What fraction of Lung adenocarcinomas have no known detactable mutations|[[42%]]}}
 
{{hidden|What are the three most common molecular alterations of Lung Adenocarcinoma|[[KRAS 23%, EGFR 15%, TP53 5%]]}}
 
{{hidden|What is the most common molecular alteration makes patients with EGFR mutations resistant to targetted therapies?|[[T790M]]}}
 
{{hidden|List two EGFR kinase inhibitors.|[[Gefitinib/Iressa, Erlotinib/Tarceva]]}}
 
{{hidden|What are the three most common cancers associated with KRAS mutations?|[[Pancreatic 90%, Colon 50%, Lung NSCLC 30%]]}}
 
{{hidden|Why don't KRAS + tumours respond to Anti EGFR therapies?|[[KRAS is downstream from EGFR, so changing the function of EFGR would not have any effect on mutated KRAS]]}}
 
{{hidden|Explain the cost effectiveness of genetic testing for targetted therapies?|[[Most molecular tests cost $200-1000, vs one month of targetted therapy $2000-10000/month]]}}


===Discussion===
{{hidden|What are the three most common cancers associated with BRAF mutations?|[[Melanoma 70%, Papillary Thyroid Carcinoma 50%, Ovarian serious carcinoma 30%, Colon cancer 10%, Hint Papillary architecture]]}}
Hi Michael, I've started, but mostly just with the questions for now, as I study I will keep working on it. Can you help me, maybe we can make additional discussion pages for each of my "study" exams,e.g. molecular, robbins chapters, cap protocols etc. This is just like LaTEX!!! 


:I hope to get a few other ppl involved.  I am just thinking about how to organize the pages. [[User:Michael|Michael]] ([[User talk:Michael|talk]]) 04:52, 14 May 2015 (EDT)
{{hidden|
Account-creators
99

edits

Navigation menu